Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine protease 53 (PRSS53) is a protein-coding gene that encodes an enzyme predicted to have serine-type endopeptidase activity, meaning it cleaves peptide bonds in proteins using a serine residue at its active site. In vitro, PRSS53 can degrade the fibrinogen alpha chain as well as pro-urokinase-type plasminogen activator, implicating a role in extracellular proteolysis. It is primarily predicted to be extracellular. This gene has been associated with certain diseases, including myxosarcoma and episodic kinesigenic dyskinesia 1. There is currently no evidence of direct interacting drugs or clinical use as a biomarker. PRSS53 is also referred to as Polyserase-3 due to its tandem serine-protease domains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine protease 53 (PRSS53).